Biomarker ID | 590 |
PMID | 21305254 |
Year | 2011 |
Biomarker | Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG); |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000]; |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(ALB):- HDL-mediated lipid transport,Transport of vitamins, nucleosides, and related molecules,Transport of organic anions,Folate metabolism,Vitamin B12 metabolism Pathways Include(APOA1):-Folate metabolism,PPAR signaling pathway,Selenium pathway, Mechanism of gene regulation by peroxisome proliferators via PPAR alpha,Vitamin B12 metabolism |
Experiment | Stage T2 Vs Stage T3 |
Type of Biomarker | Prognostic |
Cohort | Samples from 16 patients diagnosed with BPH along woth 8 patients with prostate cancer were chosen. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | MALDI-TOF-MS |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | ALB, ANXA4, APOA1, ATP5B, FGG |